Suchergebnisse - "Kinoshita, Manabu"

PubPharm (13)

1

Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma : JCOG1114C

enthalten in: Neuro-oncology | 2023

von Mishima, K. | Nishikawa, R. | Narita, Y. | +27

CommentIn: Neuro Oncol. 2023 Jan 19;:. - PMID 36655502

2

A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)

enthalten in: BMC cancer | 2021

von Arakawa, Y. | Sasaki, K. | Mineharu, Y. | +16

3

A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)

enthalten in: BMC cancer | 2021

von Arakawa, Y. | Sasaki, K. | Mineharu, Y. | +15

4

A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study)

enthalten in: Japanese journal of clinical oncology | 2019

von Kadota, T. | Saito, R. | Kumabe, T. | +9

5

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

enthalten in: Acta neuropathologica communications | 2016

von Arita, H. | Yamasaki, K. | Matsushita, Y. | +50

6

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

enthalten in: Acta Neuropathologica Communications | 2016

von Arita, H. | Yamasaki, K. | Matsushita, Y. | +50

7

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

enthalten in: Acta Neuropathologica Communications | 2016

von Arita, H. | Yamasaki, K. | Matsushita, Y. | +50

8

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma : safety and impact on immunological response

enthalten in: Cancer immunology, immunotherapy : CII | 2015

von Hashimoto, N. | Tsuboi, A. | Kagawa, N. | +15

9

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

enthalten in: Cancer immunology immunotherapy | 2015

von Hashimoto, N. | Tsuboi, A. | Kagawa, N. | +15

10

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

enthalten in: Cancer immunology immunotherapy | 2015

von Hashimoto, N. | Tsuboi, A. | Kagawa, N. | +15